{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-22-000056","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.372396+00:00","generated_at":"2026-06-22T15:15:53.172632+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Maravai Q3 revenue $191.3M, down 7% YoY; net income $99.7M; guidance updated","bullets":["Q3 revenue $191.3M (-6.6% YoY); net income $99.7M vs $132.2M prior year.","Adjusted EBITDA $132.5M (69% margin), down from $154.9M prior year.","Nucleic Acid Production revenue $174.9M, down 4% YoY; COVID-19 CleanCap revenue estimated $126.5M.","Biologics Safety Testing revenue $16.4M, down 1% YoY.","FY2022 guidance updated for revenue, Adjusted EBITDA, and Adjusted EPS; specific figures not provided in excerpt."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-22-000056","json":"https://secwatch.observer/filing/0001823239-22-000056.json","markdown":"https://secwatch.observer/filing/0001823239-22-000056.md","text":"https://secwatch.observer/filing/0001823239-22-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323922000056/0001823239-22-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323922000056/mrvi-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T15:15:53.172632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c822fd9865692a0ac06a90fff2413ee47e42154","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported third quarter ended September 30, 2022 results: revenue $191.3 million, net income $99.7 million.","evidence_excerpt":"Quarterly revenue of $191.3 million, Net income of $99.7 million, and Adjusted EBITDA margins of 69%;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323922000056/0001823239-22-000056-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$191.3 million"},{"label":"Net income","value":"$99.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}